BioStock: Saniona on the new epilepsy candidate SAN2355

Saniona ended 2023 by selecting SAN2355 as the first clinical candidate from its Kv7 epilepsy program. Having successfully passed critical candidate selection steps and secured a favourable opinion from the European Patent Office, Saniona will now advance SAN2355 into preclinical development. BioStock talked to Saniona’s CEO Thomas Feldthus to learn more about this milestone.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2024/01/saniona-on-the-new-epilepsy-candidate-san2355/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/